PROTIER Biotech Inc.

Based in South Korea, PROTIER Biotech Inc. specializes in developing innovative biopharmaceuticals, focusing on targeted therapeutics that address critical medical needs, particularly in oncology. Founded in 2022, PROTIER Biotech Inc. is headquartered in Seoul, South Korea, and operates in the biopharmaceutical sector.

The company has successfully raised KRW 3. 5 billion in its most recent funding round, enabling it to expand its research and development capabilities. The founder, Hyun-tae Kim, has a background in biopharmaceutical ventures, contributing to the company's strategic direction. To date, PROTIER Biotech has completed one funding deal.

PROTIER Biotech Inc. specializes in the development of innovative biopharmaceuticals, focusing on targeted therapeutics through proprietary platforms such as TPD (Targeted Protein Degradation) and the Molecular Glue platform. These offerings aim to improve treatment efficacy for diseases, particularly cancers, by targeting and degrading malfunctioning proteins within cells. Services are primarily directed towards healthcare providers, research institutions, and pharmaceutical companies across North America, Europe, and select Asian markets.

In 2024, PROTIER Biotech reported zero revenue. The company generates revenue through strategic partnerships and collaborations with research institutions and pharmaceutical companies via licensing agreements for its TPD and Molecular Glue platforms, alongside milestone payments related to drug development. Looking ahead, PROTIER Biotech intends to utilize its recent funding of KRW 3. 5 billion, raised in March 2026, to accelerate the entry of its drug candidates into the preclinical stage.

Plans include expanding its research pipelines to address ovarian cancer. Additionally, the company aims to enhance its market presence in North America, Europe, and Asia by collaborating with more healthcare providers and research institutions.